politics

UK Minister Supports US Pharma Deal Amid Criticism Over Medicine Costs

10 Temmuz 2026Bloomberg

UK Technology Secretary Liz Kendall has defended a controversial trade deal with the US that raises the cost of new medicines for Britain. She argues that the deal will ultimately benefit patients rather than lead to a significant increase in mortality rates.
Despite concerns from critics, Kendall maintains that the agreement is essential for improving healthcare outcomes.
The trade deal has sparked significant debate in the UK, with opponents warning that higher drug prices could lead to reduced access to essential medications. The government’s stance suggests a belief in the long-term advantages of collaboration with US pharmaceutical companies, despite immediate cost concerns.
The defense of the US pharma deal by Liz Kendall highlights the ongoing tension between healthcare affordability and access to innovative treatments. While the government emphasizes potential benefits, critics remain skeptical about the implications for public health and the financial burden on patients.

NewsAI özeti

The information provided in this summary is based on the article from Bloomberg and does not reflect the views of the editor or the newsroom.